Holen Sie sich die Stockscreener-App
1.10
0.46%
0.005
Handel nachbörslich:
1.08
-0.02
-1.82%
Schlusskurs vom Vortag:
$1.095
Offen:
$1.01
24-Stunden-Volumen:
326.65K
Relative Volume:
0.13
Marktkapitalisierung:
$35.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-87.23M
KGV:
-0.3704
EPS:
-2.97
Netto-Cashflow:
$-82.77M
1W Leistung:
-21.71%
1M Leistung:
-52.28%
6M Leistung:
-88.25%
1J Leistung:
-90.75%
1-Tages-Spanne:
$0.9817
$1.11
1-Wochen-Bereich:
$0.9817
$1.50
52-Wochen-Spanne:
$0.9817
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Firmenname
Pepgen Inc
Sektor
Branche
Telefon
703-456-8000
Adresse
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Vergleichen Sie PEPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.10 | 35.80M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-21 | Eingeleitet | H.C. Wainwright | Buy |
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
PepGen stock plunges to 52-week low of $1.14 amid market challenges - Investing.com Australia
PepGen stock plunges to 52-week low of $1.14 amid market challenges By Investing.com - Investing.com South Africa
PepGen (NASDAQ:PEPG) Stock Price Down 14.4% – Time to Sell? - Defense World
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
PepGen Announces Appointment of Two New Directors to its Board - BioSpace
PepGen Appoints Lisa Wyman and Mitchell Finer to its Board of Directors - citybiz
PepGen Inc. Expands Board with New Appointments - TipRanks
PepGen names two new directors to board - TipRanks
Strategic Power Move: PepGen Adds Clinical Development and Manufacturing Leaders to Board - Stock Titan
PepGen CMO Mellion resigns, effective April 4 - Investing.com Australia
PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen IncPEPG - Bluefield Daily Telegraph
PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money - ACCESS Newswire
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
PepGen Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsPEPG - ACCESS Newswire
PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating - TipRanks
What Do Analysts Think Will Happen To PepGen Inc (NASDAQ: PEPG) - Stocks Register
PepGen pauses Phase II DMD trial to review safety data - Clinical Trials Arena
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Marketscreener.com
Boston biotech's stock drops after Duchenne trial pause - The Business Journals
PepGen to pause CONNECT2-EDO51 study - TipRanks
PepGen slumps after pausing mid-stage study of Duchenne drug - TradingView
PepGen pauses phase 2 DMD study to review earlier trial data - Investing.com India
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD -March 04, 2025 at 08:18 am EST - Marketscreener.com
PepGen stock slides after trial pause (PEPG:NASDAQ) - Seeking Alpha
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD - TradingView
PepGen to Participate in Upcoming Investor Conferences - Business Wire
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable
PepGen (PEPG) to Release Quarterly Earnings on Wednesday - Defense World
PEPG Stock Price and Chart — NASDAQ:PEPG - TradingView
Q1 Earnings Estimate for PepGen Issued By HC Wainwright - MarketBeat
Q1 Earnings Forecast for PepGen Issued By Leerink Partnrs - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Stock Analysis: Earnings Estimates, Analyst Ratings, and Market Performance - HPBL
What is HC Wainwright’s Estimate for PepGen FY2025 Earnings? - Defense World
PepGen (PEPG) Shares Rally In Extended Session - Stocks Telegraph
Wedbush Weighs in on PepGen’s Q1 Earnings (NASDAQ:PEPG) - Defense World
HC Wainwright Reiterates Buy Rating for PepGen (NASDAQ:PEPG) - MarketBeat
Stock market news: Binah Capital Group +184.15%, PepGen +35.25% among top gainers during midday trading - Business Upturn
Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments - TipRanks
What is HC Wainwright’s Estimate for PepGen Q1 Earnings? - Defense World
PepGen CFO Noel Donnelly sells $2,565 in stock By Investing.com - Investing.com South Africa
Finanzdaten der Pepgen Inc-Aktie (PEPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):